• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia

Trendingnow

1

Trump, who has repeatedly called climate change fake, is now threatening Brazil with tariffs over the deforestation of the Amazon

2

'We didn’t see this coming': Wall Street eats its forecasts as stocks sell off globally on fear of AI bubble ahead of SpaceX IPO

3

Current price of oil as of June 8, 2026

1

Trump, who has repeatedly called climate change fake, is now threatening Brazil with tariffs over the deforestation of the Amazon

2

'We didn’t see this coming': Wall Street eats its forecasts as stocks sell off globally on fear of AI bubble ahead of SpaceX IPO

3

Current price of oil as of June 8, 2026
HealthWeight Loss

Most Americans who want to lose weight don’t want to take GLP-1 drugs like Wegovy and Zepbound, new survey says

By
Lindsey Leake
Lindsey Leake
Down Arrow Button Icon
By
Lindsey Leake
Lindsey Leake
Down Arrow Button Icon
October 10, 2024, 10:00 AM ET
Despite the ubiquitousness of injectable GLP-1 drugs indicated for people with obesity, most Americans wouldn’t take them, according to a September 2024 survey from the Physicians Committee for Responsible Medicine.
Despite the ubiquitousness of injectable GLP-1 drugs indicated for people with obesity, most Americans wouldn’t take them, according to a September 2024 survey from the Physicians Committee for Responsible Medicine.Choi Dongsu—Getty Images

GLP-1s, or glucagon-like peptide-1 agonist drugs, are seemingly everywhere. In recent years, this class of weight-loss and Type 2 diabetes medication has become not only a household name but inescapable. Shortages have dominated news headlines, and singsong commercials have taken over airwaves. GLP-1s have gone so far as to disrupt the food, clothing, and, of course, weight-loss industries.

Recommended Video

Yet despite the ubiquitousness of injectable drugs indicated for people with obesity—such as Wegovy (semaglutide), Zepbound (tirzepatide), and Saxenda (liraglutide)—most Americans wouldn’t take them, according to a new survey.

The nonprofit Physicians Committee for Responsible Medicine teamed up with business intelligence firm Morning Consult to survey more than 2,200 U.S. adults about weight-loss methods. Results of the poll, conducted in September, were released Oct. 8.

People were asked to rate their level of agreement with this statement: “If I wanted to lose weight, I would rather take an injectable weight-loss drug, rather than make a diet change.” More than half (62%) disagreed, with 14% reporting the statement didn’t apply to them because they don’t need to lose weight. Nearly three-fourths (73%) of applicable respondents disagreed.

Among people who were interested in weight loss, these groups most strongly disagreed:

  • Men: 75%
  • Baby boomers: 78%
  • Asian or “other”: 77%
  • Postgraduate-degree holders: 79%
  • Household income exceeds $100K: 78%
  • Urban dwellers: 75%
  • Northeasterners: 77%
  • Registered voters: 73%
  • Independent voters: 74%

“The new findings do not mean that Americans do not want to lose weight,” PCRM president Dr. Neal Barnard said in a news release about the survey. “Rather, most would prefer to change their eating habits than inject a medication.”

While the results offer a snapshot of public opinion, the question doesn’t capture the nuances of healthy weight loss. A calorie deficit is a critical component of weight loss but ultimately just one piece of the puzzle. Genes, sleep, stress, hormones, physical activity, and certain medications can impact weight management. Your medical history also plays a role. What’s more, GLP-1s approved for people with obesity are intended for patients who’ve had difficulty losing weight by other means, and designed to be taken in conjunction with diet and exercise.

Dr. Nisha Patel, medical director of the Obesity Medicine and Metabolic Health Program within the transplant department at California Pacific Medical Center in San Francisco, is working to dispel the myth that taking weight-loss medication is the easy way out.

“People forget that there are some strong neurohormonal factors at play that make it difficult to not only lose weight, but to keep that weight off in the long term,” Patel previously told Fortune. “Medications have really helped level the playing field. It can help interrupt some of that disruptive signaling.”

That said, GLP-1 adherence is an issue. According to a research brief published in the August issue of the Journal of Managed Care and Specialty Pharmacy, roughly one in three (32%) patients were still on their medication after a year. Fewer than that (27%) took the drug as intended.

Plant-based diet appeals to weight-loss hopefuls

The PCRM survey also asked people how much they agreed with this statement: “If a plant-based diet might cause significant weight loss, I would be interested in trying it, at least briefly.” More than half (57%) of all respondents agreed, with 17% saying they didn’t need to lose weight. More than three in five (68%) respondents looking to lose weight agreed.

Among people who were interested in weight loss, these groups most strongly agreed:

  • Women: 70%
  • Gen Zers: 81%
  • Asian or “other”: 76%
  • College and postgraduate-degree holders (tie): 69%
  • Household income exceeds $100K: 70%
  • Urban dwellers: 75%
  • Northeasterners: 70%
  • Registered voters: 69%
  • Democrats: 76%

For more on weight management:

  • Hims & Hers Super Bowl ad slams pricey pharma industry—and fumbles FDA warnings on compounded GLP-1 drugs
  • Zepbound vs. Wegovy: New clinical trial says this weight-loss medication sheds more pounds
  • The 5 biggest weight loss myths that ‘need to die,’ according to an obesity doctor
  • GLP-1 drugs like Wegovy are all the rage—but people are quitting them too fast to achieve meaningful weight loss, finds 170,000-patient study
  • This is the best time of day to exercise for people living with obesity, new study shows

Subscribe to Well Adjusted, our newsletter full of simple strategies to work smarter and live better, from the Fortune Well team. Sign up for free today.

About the Author
By Lindsey Leake
LinkedIn iconTwitter icon
See full bioRight Arrow Button Icon

Latest in Health

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025

Most Popular

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Fortune Secondary Logo
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • World's Most Admired Companies
  • See All Rankings
  • Lists Calendar
Sections
  • Finance
  • Fortune Crypto
  • Features
  • Leadership
  • Health
  • Commentary
  • Success
  • Retail
  • Mpw
  • Tech
  • Lifestyle
  • CEO Initiative
  • Asia
  • Politics
  • Conferences
  • Europe
  • Newsletters
  • Personal Finance
  • Environment
  • Magazine
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
  • Group Subscriptions
About Us
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • Pinterest icon

© 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.


Latest in Health

Kaged Pre-Workout Review (2026): Athlete Approved
HealthDietary Supplements
Kaged Pre-Workout Review (2026): Athlete Approved
By Christina SnyderJune 8, 2026
19 hours ago
Liquid IV Review (2026): Our Personal Experience
HealthDietary Supplements
Liquid IV Review (2026): Our Personal Experience
By Christina SnyderJune 8, 2026
19 hours ago
Biotics 8 Review (2026): Expert Tested
HealthDietary Supplements
Biotics 8 Review (2026): Expert Tested
By Emily PharesJune 8, 2026
19 hours ago
Jacked Factory Authentic Whey Protein Review (2026)
HealthDietary Supplements
Jacked Factory Authentic Whey Protein Review (2026)
By Emily PharesJune 8, 2026
20 hours ago
The 4 Best Calcium Supplements of 2026: Approved by Our Experts
HealthDietary Supplements
The 4 Best Calcium Supplements of 2026: Approved by Our Experts
By Christina SnyderJune 8, 2026
23 hours ago
The Best Weightlifting Apps of 2026: Programming, Coaching, and More
HealthDietary Supplements
The Best Weightlifting Apps of 2026: Programming, Coaching, and More
By Christina SnyderJune 8, 2026
24 hours ago

Most Popular

Trump, who has repeatedly called climate change fake, is now threatening Brazil with tariffs over the deforestation of the Amazon
Environment
Trump, who has repeatedly called climate change fake, is now threatening Brazil with tariffs over the deforestation of the Amazon
By Sasha RogelbergJune 8, 2026
17 hours ago
'We didn’t see this coming': Wall Street eats its forecasts as stocks sell off globally on fear of AI bubble ahead of SpaceX IPO
Economy
'We didn’t see this coming': Wall Street eats its forecasts as stocks sell off globally on fear of AI bubble ahead of SpaceX IPO
By Jim EdwardsJune 8, 2026
1 day ago
Current price of oil as of June 8, 2026
Personal Finance
Current price of oil as of June 8, 2026
By Joseph HostetlerJune 8, 2026
1 day ago
Gen Zers are arriving at college unable to even read a sentence—professors warn it could lead to a generation of anxious and lonely graduates
Success
Gen Zers are arriving at college unable to even read a sentence—professors warn it could lead to a generation of anxious and lonely graduates
By Preston ForeJune 7, 2026
2 days ago
'The golden years are not golden': Boomers are hoarding most of America's wealth and power because they're terrified of outliving their money
Economy
'The golden years are not golden': Boomers are hoarding most of America's wealth and power because they're terrified of outliving their money
By Nick LichtenbergJune 7, 2026
2 days ago
Current price of silver as of Monday, June 8, 2026
Personal Finance
Current price of silver as of Monday, June 8, 2026
By Joseph HostetlerJune 8, 2026
1 day ago